Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Heparin Fallout Likely To Impact Supplement Ingredient Testing Exemptions

This article was originally published in The Tan Sheet

Executive Summary

The discovery of adulterated ingredients in imported prescription drugs will likely cause increased scrutiny of supply chain operations for other segments across the food and drug industries

You may also be interested in...



US FDA Requests Ranitidine Removals

FDA requests immediate removal of ranitidine OTC and Rx drugs after third-party testing finds contaminant NDMA increases during storage, especially at higher temperatures. CDER Director Janet Woodcock asks firms to reformulate products to be stable as the ingredient remains approved.

US FDA Requests Ranitidine Removal But Also Encourages Research For Stable Formulations

FDA requests immediate removal of ranitidine OTC and Rx drugs after third-party testing finds contaminant NDMA increases during storage, especially at higher temperatures. CDER Director Janet Woodcock asks firms to reformulate products to be stable as the ingredient remains approved.

FDA Finds Morphine-Spiked Herbal Cough Syrup In Chinese Firm's Plant

The finding of morphine in a consumer health product made in China could rekindle concerns about lapses in supply chain security previously linked to drugs and adulterants or contaminants found in other imported FDA-regulated products.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS101530

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel